KRF Capital’s, inaugural K Energy Growth Equity Fund launches with investment in United States Sail GP Team
December 09, 2023 13:51 ET
|
KRF Capital
Dubai, UAE, Dec. 09, 2023 (GLOBE NEWSWIRE) -- KRF Capital, a female founded and led alternative asset management firm is proud to announce its strategic investment in the American SailGP racing team...
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
December 09, 2023 13:30 ET
|
Cogent Biosciences, Inc.
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated...
FSR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fisker Inc. Investors with Substantial Losses Have Opportunity to Lead Case
December 09, 2023 13:15 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, Dec. 09, 2023 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fisker Inc. (NYSE: FSR) securities between August 4, 2023...
Managers’ transactions
December 09, 2023 12:12 ET
|
BioPorto A/S
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company)...
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 09, 2023 12:00 ET
|
TScan Therapeutics, Inc.
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical...
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
December 09, 2023 12:00 ET
|
Century Therapeutics, Inc.
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – –...
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
December 09, 2023 12:00 ET
|
Corvus Pharmaceuticals, Inc.
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need...
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
December 09, 2023 12:00 ET
|
X4 Pharmaceuticals
Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to...
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
December 09, 2023 12:00 ET
|
Allogene Therapeutics, Inc.
Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile...
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
December 09, 2023 12:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67...
- December 09, 2023 13:51 ET KRF Capital’s, inaugural K Energy Growth Equity Fund launches with investment in United States Sail GP Team
- December 09, 2023 12:00 ET Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial